Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematin: effects on hemostasis.

D Green1, C H Ts'ao

  • 1Department of Medicine, Northwestern Memorial Hospital, Chicago, IL.

The Journal of Laboratory and Clinical Medicine
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.

American journal of clinical pathology·2000
Same author

Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper.

Breast cancer research and treatment·1999
Same author

Stability of plasma for add-on PT and APTT tests.

American journal of clinical pathology·1998
Same author

Advance directives in Utah. Information from death certificates and informants.

Archives of internal medicine·1996
Same author

Deep vein thrombosis in stroke. The use of plasma D-dimer level as a screening test in the rehabilitation setting.

Stroke·1996
Same author

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1996
Same journal

Studies on streptomycin; assay in body fluids.

The Journal of laboratory and clinical medicine·2010
Same journal

Gastrocolic fistula; an experimental study.

The Journal of laboratory and clinical medicine·2010
Same journal

An isolated heart perfusion system adapted to the determination of nongaseous metabolities; with sample data upon the isolated monkey heart.

The Journal of laboratory and clinical medicine·2010
Same journal

A new type of glass cage for metabolism studies.

The Journal of laboratory and clinical medicine·2010
Same journal

A simple electrocardiograph contact electrode for use with the smaller laboratory animal.

The Journal of laboratory and clinical medicine·2010
Same journal

A primary standard for the colorimetric determination of hemoglobin.

The Journal of laboratory and clinical medicine·2010
See all related articles

Degraded hematin causes bleeding disorders by affecting platelets and clotting factors. A new stable formulation, heme arginate, shows no adverse effects on coagulation, offering a safer alternative.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Hematin degradation products are known to induce coagulopathy.
  • This coagulopathy involves thrombocytopenia, platelet degranulation, and altered protein functions.
  • Endothelial cell changes and hemostatic abnormalities have been observed.

Purpose of the Study:

  • To compare the hemostatic effects of various hematin compounds.
  • To investigate the impact of degraded hematin on coagulation.
  • To evaluate the safety of heme arginate in hemostasis.

Main Methods:

  • Studies utilizing degraded hematin to assess its effects on platelet function and clotting factors.
  • Analysis of platelet aggregation, adhesion, and factor interactions.

Related Experiment Videos

  • Comparison of sorbitol-stabilized hematin and heme arginate formulations.

    • Main Results:

    • Degraded hematin stimulates platelet aggregation and adhesion.
    • It inhibits factor VIII:C dissociation and impairs factor VII/von Willebrand factor complex binding to platelets.
    • Sorbitol-stabilized hematin affects hemostasis and causes thrombophlebitis, likely due to in vivo degradation.
    • Heme arginate demonstrates stability and minimal impact on coagulation.

    Conclusions:

    • Degraded hematin significantly disrupts normal hemostasis.
    • Heme arginate represents a stable and safe alternative with no significant pro-coagulant or thrombotic effects.
    • Understanding hematin formulation is critical for managing hemostatic risks.